

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10664803
	Filing Date	2003-09-19
	First Named Inventor	Kositprapa et al.
	Art Unit	1615
	Examiner Name	Sasan, Aradhana
	Attorney Docket Number	141-424

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ^{2,1}	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1						<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.		
				<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10664803
Filing Date	2003-09-19
First Named Inventor	Kositprapa et al.
Art Unit	1615
Examiner Name	Sasan, Aradhana
Attorney Docket Number	141-424

1	EGGER M., et al., Risk of Adverse Effects of Intensified Treatment in Insulin-Dependent Diabetes Mellitus: A Meta-Analysis; Diabetic Med. 1997 Nov; 14 (11): 919-28.	<input type="checkbox"/>
2	DAILEY GE., Glyburide/Metformin Tablets: A New Therapeutic Option for The Management Of Type 2 Diabetes. Expert Opinion Pharmacotherapy (2003) 4(8): 1417-30. Review. (Abstract Only) Abstract only considered	<input type="checkbox"/>
3	BAILEY CJ, et al. Avandamet: Combined Metformin-Rosiglitazone Treatment For Insulin Resistance In Type 2 Diabetes, Int J Clin Pract (2004) Sept. 58(9): 867-76.	<input type="checkbox"/>
4	CAMPBELL, RK et al., Metformin: A New Oral Biguanide, Clin Ther (1996) May-Jun; 18(3): 360-71.	<input type="checkbox"/>
5	DAVIDSON, MB, et al., An Overview of Metformin in The Treatment of Type 2 Diabetes Mellitus, Am J Med. (1997) Jan; 102(1):99-110.	<input type="checkbox"/>
6	DUNN, CJ, et al., Metformin. A Review of its Pharmacological Properties and Therapeutic Use in Non-Insulin-Dependent Diabetes Mellitus, Drugs (1995) May; 49(5):721-49.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Aradhana Sasan/	Date Considered	05/17/2010
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.